Showing results (1961-1970 of 2,021) with videos related to

Sort By:
Pageof 203
JCO Precision Oncology|September 14, 2020
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
JCO Precision Oncology|May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.
Nature Structural & Molecular Biology|September 28, 2023
Live-cell three-dimensional single-molecule tracking reveals modulation of enhancer dynamics by NuRDS Basu, O Shukron, D Hall, et al.
Cancer Research|February 24, 2018
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast CancersFilip Mundt, Sandeep Rajput, Shunqiang Li, et al.
Breast Cancer Research and Treatment|June 26, 2021
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancerFoluso O Ademuyiwa, Ina Chen, Jingqin Luo, et al.
Annals of Internal Medicine|January 3, 2022
Knowledge Gaps, Challenges, and Opportunities in Health and Prevention Research for Asian Americans, Native Hawaiians, and Pacific Islanders: A Report From the 2021 National Institutes of Health WorkshopAlka M Kanaya, Ann W Hsing, Sela V Panapasa, et al.
Genome Medicine|November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patientsXiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Pageof 203